Core Insights - Guardant Health, Inc. announced the presentation of new data from its oncology portfolio in 15 accepted abstracts at the ESMO Congress 2025, scheduled for October 17–21 in Berlin, Germany [1] Group 1: Company Developments - The presentations will cover various aspects of cancer care treatment, including minimal residual disease (MRD) detection, recurrence monitoring, and advanced-stage tumor profiling [1]

Core Insights - Foresight Diagnostics has announced a strategic partnership with QIAGEN to develop a kit-based version of its CLARITY™ assay for minimal residual disease (MRD) detection in hematological malignancies [1][2][3] - The collaboration aims to create a standardized, regulated diagnostic kit that will be the only ctDNA-based MRD assay available for both central laboratory service and as a diagnostic kit [2][3] - This partnership is expected to enhance QIAGEN's leadership in oncology and facilitate the use of MRD insights for personalized treatment decisions in cancer patients [3] Company Overview - Foresight Diagnostics is a privately held cancer diagnostics company specializing in ultra-sensitive MRD detection with its CLARITY™ assay, which has detection limits in parts per million [4] - The CLARITY™ assay provides actionable information for personalized treatment approaches for patients with solid tumors and hematologic malignancies [4]